Genmab A/S (NASDAQ: GMAB) Stock Competitors & Peer Comparison
See GMAB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GMAB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GMAB | $28.87 | +0.80% | 17.7B | 20.77 | $1.39 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
GMAB vs VRTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas VRTX's P/E ratio is 25.35. In terms of profitability, GMAB's ROE is +0.15%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, GMAB is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
GMAB vs REGN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas REGN's P/E ratio is 16.71. In terms of profitability, GMAB's ROE is +0.15%, compared to REGN's ROE of +0.18%. Regarding short-term risk, GMAB is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
GMAB vs VRNA Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GMAB's ROE is +0.15%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, GMAB is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
GMAB vs ARGX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ARGX's P/E ratio is 78.75. In terms of profitability, GMAB's ROE is +0.15%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, GMAB is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
GMAB vs SGEN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GMAB's ROE is +0.15%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GMAB is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
GMAB vs RVMDW Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, GMAB's ROE is +0.15%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, GMAB is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
GMAB vs RVMD Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RVMD's P/E ratio is -26.52. In terms of profitability, GMAB's ROE is +0.15%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, GMAB is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
GMAB vs ONC Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ONC's P/E ratio is 70.70. In terms of profitability, GMAB's ROE is +0.15%, compared to ONC's ROE of +0.12%. Regarding short-term risk, GMAB is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
GMAB vs ALNY Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ALNY's P/E ratio is 37.02. In terms of profitability, GMAB's ROE is +0.15%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, GMAB is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
GMAB vs ROIV Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ROIV's P/E ratio is -34.86. In terms of profitability, GMAB's ROE is +0.15%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, GMAB is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
GMAB vs INCY Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas INCY's P/E ratio is 16.06. In terms of profitability, GMAB's ROE is +0.15%, compared to INCY's ROE of +0.30%. Regarding short-term risk, GMAB is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
GMAB vs BNTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas BNTX's P/E ratio is -19.61. In terms of profitability, GMAB's ROE is +0.15%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, GMAB is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
GMAB vs UTHR Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas UTHR's P/E ratio is 19.10. In terms of profitability, GMAB's ROE is +0.15%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GMAB is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
GMAB vs MRNA Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas MRNA's P/E ratio is -6.73. In terms of profitability, GMAB's ROE is +0.15%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, GMAB is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
GMAB vs INSM Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas INSM's P/E ratio is -17.15. In terms of profitability, GMAB's ROE is +0.15%, compared to INSM's ROE of -1.30%. Regarding short-term risk, GMAB is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
GMAB vs BGNE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GMAB's ROE is +0.15%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, GMAB is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
GMAB vs DNA-WT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GMAB's ROE is +0.15%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, GMAB is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
GMAB vs NBIX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas NBIX's P/E ratio is 24.10. In terms of profitability, GMAB's ROE is +0.15%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, GMAB is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
GMAB vs JAZZ Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, GMAB's ROE is +0.15%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, GMAB is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
GMAB vs BBIO Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas BBIO's P/E ratio is -21.41. In terms of profitability, GMAB's ROE is +0.15%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, GMAB is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
GMAB vs ASND Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ASND's P/E ratio is -100.79. In terms of profitability, GMAB's ROE is +0.15%, compared to ASND's ROE of -56.42%. Regarding short-term risk, GMAB is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
GMAB vs EXEL Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas EXEL's P/E ratio is 15.88. In terms of profitability, GMAB's ROE is +0.15%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, GMAB is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
GMAB vs KRTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GMAB's ROE is +0.15%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GMAB is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
GMAB vs ARWR Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ARWR's P/E ratio is -39.37. In terms of profitability, GMAB's ROE is +0.15%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, GMAB is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
GMAB vs BMRN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas BMRN's P/E ratio is 28.86. In terms of profitability, GMAB's ROE is +0.15%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, GMAB is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
GMAB vs TECH Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas TECH's P/E ratio is 37.16. In terms of profitability, GMAB's ROE is +0.15%, compared to TECH's ROE of +0.05%. Regarding short-term risk, GMAB is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
GMAB vs RNAM Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GMAB's ROE is +0.15%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, GMAB is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
GMAB vs AXSM Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas AXSM's P/E ratio is -56.92. In terms of profitability, GMAB's ROE is +0.15%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, GMAB is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
GMAB vs MDGL Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas MDGL's P/E ratio is -36.51. In terms of profitability, GMAB's ROE is +0.15%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, GMAB is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
GMAB vs SMMT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas SMMT's P/E ratio is -8.14. In terms of profitability, GMAB's ROE is +0.15%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, GMAB is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
GMAB vs KRYS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas KRYS's P/E ratio is 45.60. In terms of profitability, GMAB's ROE is +0.15%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, GMAB is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
GMAB vs HALO Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas HALO's P/E ratio is 17.87. In terms of profitability, GMAB's ROE is +0.15%, compared to HALO's ROE of +1.26%. Regarding short-term risk, GMAB is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
GMAB vs CYTK Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CYTK's P/E ratio is -13.23. In terms of profitability, GMAB's ROE is +0.15%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, GMAB is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
GMAB vs RXDX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GMAB's ROE is +0.15%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GMAB is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
GMAB vs ABVX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ABVX's P/E ratio is -65.48. In terms of profitability, GMAB's ROE is +0.15%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, GMAB is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
GMAB vs NUVL Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas NUVL's P/E ratio is -21.79. In terms of profitability, GMAB's ROE is +0.15%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, GMAB is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
GMAB vs CRNX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CRNX's P/E ratio is -16.28. In terms of profitability, GMAB's ROE is +0.15%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, GMAB is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
GMAB vs PTGX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas PTGX's P/E ratio is -75.49. In terms of profitability, GMAB's ROE is +0.15%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, GMAB is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
GMAB vs IMGN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GMAB's ROE is +0.15%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GMAB is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
GMAB vs IONS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas IONS's P/E ratio is -30.10. In terms of profitability, GMAB's ROE is +0.15%, compared to IONS's ROE of -1.11%. Regarding short-term risk, GMAB is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
GMAB vs PRAX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas PRAX's P/E ratio is -23.02. In terms of profitability, GMAB's ROE is +0.15%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, GMAB is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
GMAB vs SYRE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas SYRE's P/E ratio is -47.27. In terms of profitability, GMAB's ROE is +0.15%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, GMAB is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
GMAB vs KYMR Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas KYMR's P/E ratio is -29.29. In terms of profitability, GMAB's ROE is +0.15%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, GMAB is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
GMAB vs ALKS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ALKS's P/E ratio is 52.66. In terms of profitability, GMAB's ROE is +0.15%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, GMAB is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
GMAB vs BPMC Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GMAB's ROE is +0.15%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, GMAB is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
GMAB vs APGE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas APGE's P/E ratio is -30.97. In terms of profitability, GMAB's ROE is +0.15%, compared to APGE's ROE of -0.33%. Regarding short-term risk, GMAB is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
GMAB vs CERE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CERE's P/E ratio is -16.47. In terms of profitability, GMAB's ROE is +0.15%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GMAB is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
GMAB vs TGTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas TGTX's P/E ratio is 17.88. In terms of profitability, GMAB's ROE is +0.15%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, GMAB is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
GMAB vs IMVT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas IMVT's P/E ratio is -14.46. In terms of profitability, GMAB's ROE is +0.15%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, GMAB is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
GMAB vs PCVX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas PCVX's P/E ratio is -7.86. In terms of profitability, GMAB's ROE is +0.15%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, GMAB is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
GMAB vs IBRX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas IBRX's P/E ratio is -8.44. In terms of profitability, GMAB's ROE is +0.15%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, GMAB is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
GMAB vs MTSR Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GMAB's ROE is +0.15%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, GMAB is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
GMAB vs MRUS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GMAB's ROE is +0.15%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, GMAB is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
GMAB vs RYTM Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RYTM's P/E ratio is -31.71. In terms of profitability, GMAB's ROE is +0.15%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, GMAB is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
GMAB vs ACLX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ACLX's P/E ratio is -28.27. In terms of profitability, GMAB's ROE is +0.15%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, GMAB is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
GMAB vs COGT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas COGT's P/E ratio is -18.45. In terms of profitability, GMAB's ROE is +0.15%, compared to COGT's ROE of -0.83%. Regarding short-term risk, GMAB is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
GMAB vs RETA Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RETA's P/E ratio is -66.29. In terms of profitability, GMAB's ROE is +0.15%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GMAB is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
GMAB vs MIRM Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas MIRM's P/E ratio is -7.78. In terms of profitability, GMAB's ROE is +0.15%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, GMAB is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
GMAB vs BLTE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas BLTE's P/E ratio is -84.82. In terms of profitability, GMAB's ROE is +0.15%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, GMAB is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
GMAB vs ERAS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ERAS's P/E ratio is -19.51. In terms of profitability, GMAB's ROE is +0.15%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, GMAB is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
GMAB vs CGON Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CGON's P/E ratio is -30.55. In terms of profitability, GMAB's ROE is +0.15%, compared to CGON's ROE of -0.23%. Regarding short-term risk, GMAB is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
GMAB vs CNTA Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CNTA's P/E ratio is -22.63. In terms of profitability, GMAB's ROE is +0.15%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, GMAB is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
GMAB vs XENE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas XENE's P/E ratio is -13.33. In terms of profitability, GMAB's ROE is +0.15%, compared to XENE's ROE of -0.49%. Regarding short-term risk, GMAB is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
GMAB vs LGND Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas LGND's P/E ratio is 34.48. In terms of profitability, GMAB's ROE is +0.15%, compared to LGND's ROE of +0.16%. Regarding short-term risk, GMAB is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
GMAB vs SRRK Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas SRRK's P/E ratio is -13.17. In terms of profitability, GMAB's ROE is +0.15%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, GMAB is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
GMAB vs PTCT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas PTCT's P/E ratio is -29.19. In terms of profitability, GMAB's ROE is +0.15%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, GMAB is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
GMAB vs CDTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GMAB's ROE is +0.15%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, GMAB is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
GMAB vs ABCM Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GMAB's ROE is +0.15%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GMAB is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
GMAB vs ISEE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GMAB's ROE is +0.15%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GMAB is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
GMAB vs APLS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas APLS's P/E ratio is 38.35. In terms of profitability, GMAB's ROE is +0.15%, compared to APLS's ROE of +0.40%. Regarding short-term risk, GMAB is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
GMAB vs TVTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas TVTX's P/E ratio is -254.05. In terms of profitability, GMAB's ROE is +0.15%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, GMAB is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
GMAB vs TERN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas TERN's P/E ratio is -51.41. In terms of profitability, GMAB's ROE is +0.15%, compared to TERN's ROE of -0.20%. Regarding short-term risk, GMAB is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
GMAB vs DFTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas DFTX's P/E ratio is N/A. In terms of profitability, GMAB's ROE is +0.15%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, GMAB is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
GMAB vs DYN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas DYN's P/E ratio is -7.82. In terms of profitability, GMAB's ROE is +0.15%, compared to DYN's ROE of -0.64%. Regarding short-term risk, GMAB is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
GMAB vs CRSP Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CRSP's P/E ratio is -9.39. In terms of profitability, GMAB's ROE is +0.15%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, GMAB is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
GMAB vs FOLD Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas FOLD's P/E ratio is -161.00. In terms of profitability, GMAB's ROE is +0.15%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, GMAB is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
GMAB vs AKRO Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GMAB's ROE is +0.15%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, GMAB is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
GMAB vs DNTH Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas DNTH's P/E ratio is -25.89. In terms of profitability, GMAB's ROE is +0.15%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, GMAB is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
GMAB vs ALPN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GMAB's ROE is +0.15%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GMAB is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
GMAB vs ACAD Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ACAD's P/E ratio is 12.68. In terms of profitability, GMAB's ROE is +0.15%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, GMAB is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
GMAB vs CAI Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CAI's P/E ratio is -86.19. In terms of profitability, GMAB's ROE is +0.15%, compared to CAI's ROE of +0.06%. Regarding short-term risk, GMAB is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
GMAB vs MANE Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas MANE's P/E ratio is -33.36. In terms of profitability, GMAB's ROE is +0.15%, compared to MANE's ROE of -0.84%. Regarding short-term risk, GMAB is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
GMAB vs OPT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas OPT's P/E ratio is -1.52. In terms of profitability, GMAB's ROE is +0.15%, compared to OPT's ROE of +1.18%. Regarding short-term risk, GMAB is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
GMAB vs PRTC Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas PRTC's P/E ratio is -3.78. In terms of profitability, GMAB's ROE is +0.15%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, GMAB is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
GMAB vs CELC Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CELC's P/E ratio is -22.15. In terms of profitability, GMAB's ROE is +0.15%, compared to CELC's ROE of -2.45%. Regarding short-term risk, GMAB is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
GMAB vs EWTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas EWTX's P/E ratio is -23.15. In terms of profitability, GMAB's ROE is +0.15%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, GMAB is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
GMAB vs MRTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GMAB's ROE is +0.15%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GMAB is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
GMAB vs ELVN Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ELVN's P/E ratio is -32.82. In terms of profitability, GMAB's ROE is +0.15%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, GMAB is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
GMAB vs CPRX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CPRX's P/E ratio is 12.30. In terms of profitability, GMAB's ROE is +0.15%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GMAB is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
GMAB vs RYZB Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GMAB's ROE is +0.15%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GMAB is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
GMAB vs CBAY Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GMAB's ROE is +0.15%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GMAB is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
GMAB vs VKTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas VKTX's P/E ratio is -7.67. In terms of profitability, GMAB's ROE is +0.15%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, GMAB is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
GMAB vs DNLI Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas DNLI's P/E ratio is -7.99. In terms of profitability, GMAB's ROE is +0.15%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, GMAB is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
GMAB vs ORKA Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ORKA's P/E ratio is -49.75. In terms of profitability, GMAB's ROE is +0.15%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, GMAB is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
GMAB vs ADPT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ADPT's P/E ratio is -41.80. In terms of profitability, GMAB's ROE is +0.15%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, GMAB is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
GMAB vs ALMS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ALMS's P/E ratio is -7.39. In terms of profitability, GMAB's ROE is +0.15%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, GMAB is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
GMAB vs RCUS Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas RCUS's P/E ratio is -8.66. In terms of profitability, GMAB's ROE is +0.15%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, GMAB is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
GMAB vs SWTX Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GMAB's ROE is +0.15%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, GMAB is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
GMAB vs ARQT Comparison August 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 17.7B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, GMAB is priced at $28.87 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 20.77, whereas ARQT's P/E ratio is -933.00. In terms of profitability, GMAB's ROE is +0.15%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, GMAB is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ARQT's competition here